Open Access

Fibrinogen‑to‑albumin ratio predicts long‑term outcomes for patients with ST‑elevation myocardial infarction and multivessel disease: A prospective observational cohort study

  • Authors:
    • Gao Liu
    • Chuan-Min Fan
    • Hao Guo
    • Wei-Na Fan
    • Ming-Liang Li
    • Guo-Xiong Cui
  • View Affiliations

  • Published online on: March 8, 2021     https://doi.org/10.3892/etm.2021.9896
  • Article Number: 465
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The fibrinogen‑to‑albumin ratio index (FAR) is a valuable tool reflecting the systemic inflammation level and associated with the severity of coronary artery disease. However, the utility of the FAR in predicting the long‑term prognosis of patients with ST‑elevation myocardial infarction (STEMI) and multivessel disease has remained to be determined. A total of 424 patients diagnosed with STEMI and multivessel disease were recruited for the present study. They were given emergent percutaneous coronary intervention treatment and then completed a follow‑up for primary (all‑cause mortality) and secondary endpoints (major adverse cardiac events, including MI, stroke, emergent revascularization and rehospitalization due to heart failure). The association between FAR and the Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score was investigated, while receiver operating characteristic curve analysis was adopted to assess the ability of the FAR to predict long‑term outcomes. The long‑term survival of high and low FAR groups was compared by drawing Kaplan‑Meier survival curves. Multivariate Cox regression analysis was adopted to evaluate the risk factors of primary and secondary endpoints. The FAR was revealed to have a linear correlation with the SYNTAX score (y=0.022x+17.737; P=0.015). Furthermore, the FAR was a significant predictor of all‑cause death with a cut‑off value of 128.4 (area under the curve, 0.832; P<0.001). A significant difference was determined between the high FAR group and the low FAR group in terms of the proportion of patients with the primary endpoint (P<0.001) and secondary endpoint (P=0.001). It was demonstrated that the FAR was an independent risk factor for all‑cause death of patients with STEMI and multivessel disease (hazard ratio, 1.029; 95% CI: 1.020‑1.037; P<0.001). In summary, the FAR is a valuable biomarker associated with STEMI and may be useful in the prediction of the long‑term prognosis of patients with STEMI and multivessel disease.
View Figures
View References

Related Articles

Journal Cover

May-2021
Volume 21 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu G, Fan C, Guo H, Fan W, Li M and Cui G: Fibrinogen‑to‑albumin ratio predicts long‑term outcomes for patients with ST‑elevation myocardial infarction and multivessel disease: A prospective observational cohort study. Exp Ther Med 21: 465, 2021
APA
Liu, G., Fan, C., Guo, H., Fan, W., Li, M., & Cui, G. (2021). Fibrinogen‑to‑albumin ratio predicts long‑term outcomes for patients with ST‑elevation myocardial infarction and multivessel disease: A prospective observational cohort study. Experimental and Therapeutic Medicine, 21, 465. https://doi.org/10.3892/etm.2021.9896
MLA
Liu, G., Fan, C., Guo, H., Fan, W., Li, M., Cui, G."Fibrinogen‑to‑albumin ratio predicts long‑term outcomes for patients with ST‑elevation myocardial infarction and multivessel disease: A prospective observational cohort study". Experimental and Therapeutic Medicine 21.5 (2021): 465.
Chicago
Liu, G., Fan, C., Guo, H., Fan, W., Li, M., Cui, G."Fibrinogen‑to‑albumin ratio predicts long‑term outcomes for patients with ST‑elevation myocardial infarction and multivessel disease: A prospective observational cohort study". Experimental and Therapeutic Medicine 21, no. 5 (2021): 465. https://doi.org/10.3892/etm.2021.9896